Domainex Ltd wins biotechnology innovation award
Domainex Ltd, won the Innovation in Enabling biotechnology Award at the 2007 UK BioEntrepreneurial Company of the Year Awards, presented by UK Trade & Investment in London 4th. More than 180 industry leaders attended the annual ceremony, which recognises innovation and entrepreneurship in the biotechnology industry.
Dr Renos Savva (right) receives the award from Andrew Cahn (left)
Domainex
Dr Renos Savva, one of the company's founders and the CEO of Domainex, Dr Eddy Littler, received the award from Mr Andrew Cahn, CEO of UK Trade & Investment. "We are delighted to have been presented with this award, which recognises our commitment to developing new technologies for streamlining and accelerating the drug discovery process," said Dr Savva.
Domainex Ltd has developed a unique high-throughput technology for producing soluble and stable protein fragments that are suitable for compound screening, structural biology studies or antibody production. The approach resolves the discovery 'gap' that exists between the vast amount of genomic information that is now available, and the accessibility of the corresponding proteins for use in target validation and drug discovery.
Most read news
Other news from the department business & finance
Get the analytics and lab tech industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Sequenom Announces European Licensing Agreement With LifeCodexx
Waters to Acquire Andrew Alliance
Gold shines through properties of nano biosensors - Fluorescence in ligand-protected gold nanoclusters is an intrinsic property of the gold particles themselves
Out of REACH - New legislation threatens medicines
Neutrons for the quantum technologies of the future: breakthrough results on layered perovskites
200-year long dispute resolved: First direct evidence that elemental fluorine occurs in nature
Dow acquires Rohm and Haas, creating world's leading specialty chemicals and advanced materials company - $18.8 billion transaction marks pivotal point in Dow's transformation
Seeing a diagnosis: How an eye test could aid Alzheimer's detection